Lv3
376 积分 2024-11-01 加入
Oral vancomycin is not associated with meaningful changes in liver-related endpoints among adults with primary sclerosing cholangitis: A randomized, placebo-controlled trial
24天前
已完结
Effects of combined prebiotic fiber supplementation and weight loss counseling in adults with metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial
27天前
已完结
Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial
29天前
已关闭
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma
30天前
已完结
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
1个月前
已完结
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
1个月前
已完结
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
1个月前
已完结
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
1个月前
已完结
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC
1个月前
已完结
皖公网安备34019202002308
